

Special Issue

Tuberculosis Vaccines and Novel Drug Development

Message from the Guest Editors

Tuberculosis (TB) continues to be a major global health burden and kills over a million people annually. The emergence of drug-resistant strains has further worsened the situation that demands urgent need for vaccines and novel drug development against *Mycobacterium tuberculosis* (Mtb). The attenuated *Mycobacterium bovis* strain Bacille Calmette–Guerin (BCG) is the only FDA-licensed TB vaccine. BCG protects infants against disseminated TB, but it shows variable protection against adult pulmonary TB. Moreover, BCG can disseminate under immunosuppressed or immunocompromised conditions; hence, a safer and more efficacious TB vaccine is paramount. This requires a better understanding of the mechanisms that Mtb deploys to evade the host immune response. This Special Issue welcomes all types of manuscripts providing insight into aspects relevant to TB vaccines and novel drug development. We are interested in a wide scope of work including but not limited to basic science research and clinical studies. We welcome the submission of original articles, reviews and other research articles that will improve our knowledge in these areas.

Guest Editors

Dr. Sangeeta Tiwari

Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA

Dr. Shivani Singh

Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA

Deadline for manuscript submissions

closed (31 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/183454

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).